Crispr has already secured a historic first approval for a CRISPR/Cas9 drug and has several more potential blockbuster ...

Orsini has been chosen by Vertex Pharmaceuticals Incorporated to dispense gene-editing therapy CASGEVY® (exagamglogene ...

That's where CRISPR Therapeutics falls short. The company's approved product, Casgevy, is an ex vivo gene editing treatment.

It’s been a year since the gene-editing treatment Casgevy was approved for sickle cell disease and a related blood disorder.

I also expect both to become huge commercial successes for Vertex. Second, the big biotech company's launch of Casgevy is ...

We recently compiled a list of the ARK Invest Stock Portfolio: Top 10 Stock Picks for 2024. In this article, we are going to ...

With a bunch of gene therapy and gene editing programs in clinical trials, CRISPR Therapeutics (NASDAQ: CRSP) has an ...

ARK Investment Management LLC, more commonly known as ARK Invest, is an American investment management firm headquartered in ...

The launch of Casgevy, CRISPR Therapeutics' gene therapy for sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT), represents a significant milestone for the company.

ELK GROVE VILLAGE, Ill., Nov. 14, 2024 /PRNewswire/ -- Orsini has been chosen by Vertex Pharmaceuticals Incorporated to dispense gene-editing therapy CASGEVY® (exagamglogene autotemcel).